CommercialCoverageMedium impact
08.01.32p, Efbemalenograstim alfa-vuxw (Ryzneuta®), Eflapegrastim-xnst (Rolvedon™), Pegfilgrastim (Neulasta®) and Related Biosimilars
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 20, 2026
We identified it
Jun 19, 2026
Summary
This policy update modifies medical necessity criteria, billing codes, and general guidelines for granulocyte colony-stimulating factor medications including Ryzneuta, Rolvedon, Neulasta and related biosimilars. The changes affect pharmacy coverage policies for these cancer supportive care medications used to prevent neutropenia.
Action Required
Before April 20, 2026: Billing team must review and update medical necessity documentation requirements for granulocyte colony-stimulating factor medications (Ryzneuta, Rolvedon, Neulasta and biosimilars). Update prior authorization workflows and billing system edits to reflect new criteria. Notify oncology providers of any documentation changes to ensure compliance with updated policy requirements.